SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001839882-22-030195
Filing Date
2022-12-27
Accepted
2022-12-27 16:06:25
Documents
12
Period of Report
2022-12-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT smmt-8k_122222.htm   iXBRL 8-K 26205
  Complete submission text file 0001839882-22-030195.txt   202535

Data Files

Seq Description Document Type Size
2 XBRL LABEL FILE smmt-20221222_lab.xml EX-101.LAB 34916
3 XBRL PRESENTATION FILE smmt-20221222_pre.xml EX-101.PRE 22773
4 XBRL SCHEMA FILE smmt-20221222.xsd EX-101.SCH 3203
6 EXTRACTED XBRL INSTANCE DOCUMENT smmt-8k_122222_htm.xml XML 3766
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 221490353
SIC: 2834 Pharmaceutical Preparations